Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

gene amplification in their tumours (metastatic or primary) in order to qualify for the trial.

The primary objectives of the Phase 2 trial are to determine the objective response rate of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, and to measure progression-free survival at 6 months. The secondary objectives are to determine the median survival and duration of progression-free survival in patients, and to evaluate the safety and tolerability of REOLYSIN(R) in combination with paclitaxel and carboplatin in this patient population.

REOLYSIN(R) preferentially replicates in cancer cells that have an activated RAS pathway. Approximately two thirds of all cancers have an activated RAS pathway, including most metastatic disease. A large number of mutations, including mutations in EGFR, Her2 or K-RAS along the RAS pathway lead to RAS pathway activation.

Recent clinical studies in NSCLC with EGFR-based therapies have shown that patients with mutations or overexpression of EGFR, which are commonly found in NSCLC, derive clinical benefit from these therapies. An agent such as REOLYSIN(R) that selectively replicates in cancers with an activated RAS pathway resulting from EGFR mutations or overexpression may show similar benefit. However, patients with mutant K-RAS, or up to 20% of the more than 180,000 patients diagnosed every year in the U.S. with NSCLC, do not derive benefit from EGFR-based therapies. The introduction of screening for K-RAS mutations, and the exclusion of K-RAS mutated patients will lead to higher response rates in EGFR-mutated or overexpressed patients treated with EGFR-based therapies. This excluded patient group is therefore prescreened for RAS pathway activation resulting from mutations in K-RAS, and an agent such as REOLYSIN(R) may be indicated for this patient group. This study targets patients with either EGFR-activated tumours or K
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
(Date:7/25/2014)... July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, oral ... gallstones, today announced financial results for the period ended ... Summary: , Reported cash and cash equivalents totaling ... at December 31, 2013.  , Reported a net ...
(Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... Materials Research Laboratory at UC Santa Barbara: an NSF ... from the National Science Foundation (NSF) to carry out ... years. Renewed NSF support ensures the vitality of materials ... energy, environment, and sustainability. Despite the challenging budgetary ...
... Sept. 12, 2011 McKesson Corporation ... McKesson Specialty Health , focused on empowering the ... technology and quality of care. (Logo:   ... support and business solutions, McKesson Specialty Health offers the ...
... Sept. 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... the Rodman & Renshaw Annual Global Investment Conference on Tuesday, ... will be held at The Waldorf Astoria in New York, ... Executive Officer of Palatin Technologies, will provide an update on ...
Cached Biology Technology:Major grant from the National Science Foundation will sustain UCSB materials research through 2017 2Major grant from the National Science Foundation will sustain UCSB materials research through 2017 3McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System 2McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System 3
(Date:7/24/2014)... billion years of evolutionary trial and error, is the ... be reaching a tipping point. , In a new ... in Science , an international team of scientists ... contributing to what appears to be the early days ... Since 1500, more than 320 terrestrial vertebrates have become ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva ... Fox Foundation for Parkinson,s Research to translate a basic ... drug discovery project will test chemical compounds on a ... drug that acts on an underlying cause of the ... many people manage their symptoms, we are eager to ...
(Date:7/24/2014)... is a hotspot of biodiversity and one of the ... toads) in the world. However, current levels of diversity ... has been an increase in the description of new ... of molecular techniques and availability of samples for DNA ... samples for molecular and morphological analysis, researchers from the ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A tiny new species of frog from Brazil with a heroic name 2
... ON, July 19, 2013 Kidney patients who take calcium ... 22 per cent higher risk of death than those who ... by Women,s College Hospital,s Dr. Sophie Jamal. The study, ... the long-time practice of prescribing calcium to lower phosphate levels ...
... This news release is available in German . ... of text, the brain sends commands to arms and fingers to tap ... transfer this information as electrical pulses that trigger muscles to move. The ... along the spinal cord. For a long time, scientists assumed that ...
... media has expanded to reach an unlikely new target: ... Technology (NIST) have created networks of molecular data similar ... search would allow Facebook users to find all their ... NIST-designed networks could help scientists rapidly sift through enormous ...
Cached Biology News:Calcium linked to increased risk of heart disease and death in patients with kidney disease 2Haste and waste on neuronal pathways 2Haste and waste on neuronal pathways 3Haste and waste on neuronal pathways 4Facebook for molecules 2Facebook for molecules 3
capacity 250 mL...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z35,347-7) ...
Certified by the Biological Stain Commission. For staining fresh peripheral blood smears and blood parasites....
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Biology Products: